With the acquisition of SentrX Animal Care, Inc. Dômes Pharma expands its global leadership in veterinary ophthalmology while creating a launching pad for its therapeutic product franchises in North America Pont-du-Château, August 16, 2023 – Dômes Pharma announces that it has finalized the acquisition of SentrX Animal Care, a US company based in Salt Lake City (Utah). SentrX develops and manufactures ophthalmology products based on its exclusive BioHAnce™ technology. BioHAnce™ is a patented crosslinked Hyaluronic Acid technology that enhances and accelerates natural healing, hydration and lubrication processes, while reducing the number of applications. The company, which has its own 2,000 m2 manufacturing plant, markets 3 products that have rapidly gained market share in the United States and Europe, notably in the UK, thanks to their effectiveness and ease of use. Less than a year after the opening...

We are pleased to announce the launch of Sentrx Eye Lube Pro, a solution to the demand for bulk lubrication during anesthetic procedures and a value-based approach to long-term lubrication needs. Taking advantage of our vertically integrated in-house manufacturing capabilities, Sentrx is able to produce a cost-effective bulk lubricant and pass the savings on to our veterinary customers.

We are pleased to announce that Provet® has partnered with SentrxTM Animal Care as the exclusive distributor representing the patented crosslinked Hyaluronic Acid BioHAnce® brand of products in in Australia. Effective September 28, 2022 Sentrx ophthalmology products: Ocunovis™ BioHAnce™ Gel Eye Drops, Oculenis™ BioHAnce™ Ocular Barrier Gel will be available through Provet® to all authorized veterinary customers. All Sentrx products feature patented and clinically proven BioHAnce technology of which millions of doses have been sold globally to veterinarians*. This partnership allows veterinarians in Australia to prescribe the first and only formulation with cross-linked hyaluronic acid (HA). The cross-linking of BioHAnce provides the longest lasting ocular lubrication on the market. That promotes consistency of the tear film and enhances the eye’s ability to maintain hydration. “The benefits of topical hyaluronic acid (HA) use are well known within the global veterinary ophthalmology community, so it is...

SALT LAKE CITY, UT: Sentrx, an animal health company that transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals, today announced the formation of a US-based Ophthalmology Scientific and Medical Advisory Board (OSMAB) comprised of veterinary and scientific leaders in ophthalmology and clinical trial design. The board will be chaired by Chief Scientific Officer, Sarah Atzet, Ph.D. and will work closely with management to advance the company’s clinical pipeline development in the US and the utility of its platform BioHAnceTM technology, a patented molecular matrix of cross-linked hyaluronic acid (HA). “We’ve assembled a board of prestigious scientific and medical thought leaders to provide Sentrx with relevant and informed counsel in the months and years ahead, as we continue our research and application efforts and development of disruptive innovation in the veterinary...